Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Oxervate (cenegermin-bkbj) to Treat Neurotrophic Keratitis, US

Drug Name

Oxervate™ (cenegermin-bkbj)

Developer

Dompé

Therapy Class

Ophthalmic solution

Product Description

Recombinant human nerve growth factor

Current Indication

Neurotrophic keratitis

Market Sector

Ophthalmology

Development Status

Approved in the US and Europe
Expand
Close
Close
Close

Go Top